Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream

Journal of Drugs in Dermatology

Volumn 10, Issue 2, 2011, Pages 165-170

  Hanke, C William ^a   Swanson, Neil ^b   Bruce, Suzanne ^c   Berman, Brian ^d   Kulp, James ^e   Levy, Sharon ^e  

^a Laser and Skin Surgery Center of Indiana   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Center for Skin Research   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Graceway Pharmaceuticals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PLACEBO; AMINOQUINOLINE DERIVATIVE;

ACTINIC KERATOSIS; ADULT; AGED; ALOPECIA; APPLICATION SITE SCAR; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG SAFETY; FACE DISORDER; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; TREATMENT DURATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FACE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCALP; TIME; TREATMENT OUTCOME;

ADULT; AMINOQUINOLINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACE; HUMANS; KERATOSIS, ACTINIC; MALE; SCALP; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052054177     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Zyclara™ (imiquimod cream, 3.75%) prescribing information, Graceway Pharmaceuticals, LLC, Bristol, TN. March 2010.
2. Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009;8:467-474.
3. Aldara® (imiquimod cream, 5%) prescribing information, Graceway Pharmaceuticals, LLC, Bristol, TN. April 2009.
4. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721. (Pubitemid 38580548)
5. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582-590.
6. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573-581.
7. Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg. 2005;31:659-664.
8. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265-268. (Pubitemid 47048863)
9. Yantsos VA, Conrad N, Zabawski E, Cockerell CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: A proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999;18:3-14. (Pubitemid 29165093)
10. Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: A spectrum of disease progression. Arch Dermatol. 2010;146:288-293.
11. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995;32:95 98.
12. Braakhuis BJ, Tabor MP, Jummer JA, et al. A genetic explanation for Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res. 2003;63:1727 1730.
13. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157 Suppl 2:21-24. (Pubitemid 350179625)
14. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467-473. (Pubitemid 40547405)
15. Torres A, Storey L, Anders M, et al. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med. 2007;5:7.
16. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol. 2006;154:72-78. (Pubitemid 43381323)
17. Huang SJ, Hijnen D, Murphy GF, et al. Imiquimod enhances IFN gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009;129:2676-2685.
18. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205:2221-2234.
19. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, doubleblinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9:1101-1108.